Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

S Wolking, E Schaeffeler, H Lerche, M Schwab… - Clinical …, 2015 - Springer
ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …

Drug resistance: still a daunting challenge to the successful treatment of AML

BC Shaffer, JP Gillet, C Patel, MR Baer, SE Bates… - Drug Resistance …, 2012 - Elsevier
Resistance to chemotherapy remains a challenging issue for patients and their physicians. P-
glycoprotein (Pgp, MDR1, ABCB1), as well as a family of structurally and functionally related …

Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs

I Cascorbi - Pharmacology & therapeutics, 2006 - Elsevier
Interindividual differences of drug response are an important cause of treatment failures and
adverse drug reactions. The identification of polymorphisms explaining distinct phenotypes …

Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance

O Bruhn, I Cascorbi - Expert opinion on drug metabolism & …, 2014 - Taylor & Francis
Introduction: Human ATP-binding cassette (ABC) transporters act as translocators of
numerous substrates across extracellular and intracellular membranes, thereby contributing …

P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations

I Cascorbi - Drug transporters, 2011 - Springer
Abstract P-glycoprotein (ABCB1, MDR1) belongs to the ABC transporter family transporting
a wide range of drugs and xenobiotics from intra-to extracellular at many biological …

Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression

S Nobili, I Landini, T Mazzei… - Medicinal research reviews, 2012 - Wiley Online Library
Multidrug resistance (MDR) is a major obstacle to the effective treatment of cancer. Cellular
overproduction of P‐glycoprotein (P‐gp), which acts as an efflux pump for various anticancer …

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia

DH Kim, L Sriharsha, W Xu, S Kamel-Reid, X Liu… - Clinical cancer …, 2009 - AACR
Purpose: Imatinib resistance is major cause of imatinib mesylate (IM) treatment failure in
chronic myeloid leukemia (CML) patients. Several cellular and genetic mechanisms of …

ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise

LW Chinn, DL Kroetz - Clinical Pharmacology & Therapeutics, 2007 - Wiley Online Library
In 1976, Juliano and Ling 1 reported expression of a 170 kDa protein in colchicine‐resistant
Chinese hamster ovary (CHO) cells that was absent in drug‐sensitive cells. Because this …

Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy

Y Huang - Cancer and Metastasis Reviews, 2007 - Springer
Inter-individual variability in drug response and the emergence of adverse drug reactions
are main causes of treatment failure in cancer therapy. Recently, membrane transporters …

Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation

CQ Xia, PG Smith - Molecular pharmacology, 2012 - ASPET
Multidrug resistance (MDR), which is mediated by multiple drug efflux ATP-binding cassette
(ABC) transporters, is a critical issue in the treatment of acute leukemia, with permeability …